Vericel Co. (NASDAQ:VCEL) Shares Purchased by Bank of Montreal Can

Bank of Montreal Can boosted its position in Vericel Co. (NASDAQ:VCEL) by 17.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,217 shares of the biotechnology company’s stock after purchasing an additional 919 shares during the quarter. Bank of Montreal Can’s holdings in Vericel were worth $341,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Federated Hermes Inc. increased its holdings in Vericel by 25.4% in the fourth quarter. Federated Hermes Inc. now owns 1,122,373 shares of the biotechnology company’s stock valued at $61,630,000 after buying an additional 227,675 shares during the last quarter. Wells Fargo & Company MN increased its position in Vericel by 11.8% during the fourth quarter. Wells Fargo & Company MN now owns 69,975 shares of the biotechnology company’s stock worth $3,842,000 after buying an additional 7,363 shares in the last quarter. Scholtz & Company LLC increased its stake in Vericel by 10.6% in the fourth quarter. Scholtz & Company LLC now owns 47,660 shares of the biotechnology company’s stock valued at $2,617,000 after purchasing an additional 4,562 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Vericel in the 4th quarter valued at about $4,884,000. Finally, Geode Capital Management LLC lifted its stake in shares of Vericel by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,166,115 shares of the biotechnology company’s stock worth $64,046,000 after purchasing an additional 12,062 shares in the last quarter.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 24,850 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the completion of the transaction, the chief executive officer now directly owns 260,354 shares in the company, valued at $10,906,229.06. The trade was a 8.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,942 shares of company stock valued at $2,724,548 in the last three months. 5.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently commented on VCEL. Stephens reiterated an “overweight” rating and issued a $65.00 price target on shares of Vericel in a research note on Wednesday, January 15th. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Vericel in a research note on Friday, February 28th. Canaccord Genuity Group lifted their price target on Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Truist Financial lowered their price target on Vericel from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.86.

Vericel Trading Up 1.6 %

Shares of VCEL stock opened at $40.05 on Thursday. Vericel Co. has a 1 year low of $37.76 and a 1 year high of $63.00. The firm’s fifty day moving average price is $46.43 and its two-hundred day moving average price is $51.29. The firm has a market capitalization of $2.01 billion, a P/E ratio of 667.61 and a beta of 1.61.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.